The concept of "tailor-made", protein-based, outer membrane vesicle vaccines against meningococcal disease

Vaccine

Volumn 23, Issue 17-18, 2005, Pages 2202-2205

  Holst, Johan ^a   Feiring, Berit ^a   Næss, Lisbeth M ^a   Norheim, Gunnstein ^a   Kristiansen, Paul ^a   Høiby, E Arne ^a   Bryn, Klaus ^a   Oster, Philipp ^b   Costantino, Paolo ^b   Taha, Muhamed Kheir ^c   Alonso, Jean Michel ^c   Caugant, Dominique A ^a   Wedege, Elisabeth ^a   Aaberge, Ingeborg S ^a   Rappuoli, Rino ^b   Rosenqvist, Einar ^a  

^a NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^b CHIRON VACCINES   (Italy)

^c INSTITUT PASTEUR   (France)

Author keywords

Meningococcal disease; Outer membrane vesicle (OMV) vaccines; Serum bactericidal activity (SBA)

Indexed keywords

BACTERIAL ANTIGEN; INVASIN; MENINGOCOCCUS VACCINE; OUTER MEMBRANE PROTEIN; PORIN A; PORIN B; REDUCTION MODIFIABLE PROTEIN; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; AFRICA; CLINICAL TRIAL; CONFERENCE PAPER; CUBA; DRUG APPROVAL; DRUG EFFICACY; EPIDEMIC; FRANCE; HEALTH PROGRAM; HUMAN; IMMUNOGENICITY; INCIDENCE; INFECTION CONTROL; MEMBRANE VESICLE; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; NEW ZEALAND; NORWAY; PHENOTYPE; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; SCALE UP; STANDARDIZATION; VACCINE PRODUCTION;

EID: 20044392859     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2005.01.058     Document Type: Conference Paper

References (18)

1. Frasch CE, van Alphen L, Holst J, Poolman J, Rosenqvist E. Preparation of outer membrane protein vaccines against meningococcal disease. In: Pollard AJ, Maiden MCJ, editors. Methods in molecular medicine, 66: meningococcal disease protocols. Totowa, NJ; Humana Press Inc.; 2001. 81-107 [chapter 55].
2. I. Goldschneider, E.C. Gotschlich, and M.S. Artenstein Human immunity to the meningococcus: II. Development of natural immunity J Exp Med 129 1969 1327 1348
3. J. Holst, B. Feiring, J.E. Fuglesang, E.A. Høiby, H. Nøkleby, and I.S. Aaberge Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease Vaccine 21 2003 734 737
4. P. Balmer, and R. Borrow Serological correlates of protection for evaluating the response to meningococcal vaccines Expert Rev Vaccines 3 2004 77 87
5. Sierra GVG, H.C. Campa, N.M. Varcacel, I.L. Garcia, P.L. Izquierdo, and P.F. Sotolongo Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba NIPH Ann 14 1991 195 207
6. G. Bjune, E.A. Høiby, J.K. Grønnesby, Ø. Arnesen, J. Holst Fredriksen, and A. Halstensen Effect of outer membrane vesicle vaccine against serogroup B meningococcal disease in Norway Lancet 338 1991 1093 1096
7. E. Rosenqvist, E.A. Høiby, E. Wedege, K. Bryn, J. Kolberg, and A. Klem Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine Infect Immun 12 1995 4642 4652
8. J.W. Tappero, R. Lagos, A.M. Ballesteros, B. Plikaytis, D. Williams, and J. Dykes Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile JAMA 281 1999 1520 1527
9. J. Holst, I.S. Aaberge, P. Oster, D. Lennon, D. Martin, and J. O'Hallahan A 'tailor made' vaccine trialled as part of public health response to group B meningococcal epidemic in New Zealand Eurosurveillance Weekly 7 2003 030724
10. D.R. Martin, S.J. Walker, M.G. Baker, and D.R. Lennon New Zealand epidemic of meningococcal disease identified by a strain with phenotype B:4:P1.4 J Infect Dis 177 1998 497 500
11. Martin D, McDowell R, Sneyd E, Baker M. The epidemiology of meningococcal disease in New Zealand in 2002. Report prepared for the Ministry of Health by the Institute of Environmental Science and Research Limited. Wellington: Ministry of Health, May 2003; p. 1-64. Available at http://www.moh.govt.nz.
12. S.H. Wong, C.M. Jackson, D.M. Martin, J. O'Hallahan, P. Oster, and J.M. Stewart Safety and immunogenicity of New Zealand strain meningococcal serogroup B outer membrane vesicle vaccine in healthy 16-24 months old toddlers M.A. Apicella H. Seifert Fourteenth International Pathogenic Neisseria Conference Milwaukee, Wisconsin, USA 2004 8
13. D.A. Caugant Population genetics and molecular epidemiology of Neisseria meningitidis APMIS 106 1998 505 525
14. G. Norheim, E.A. Høiby, D.A. Caugant, E. Namork, T. Tangen, and E. Fritzsønn Immunogenicity and bactericidal activity in mice of an outer membrane protein vesicle vaccine against Neisseria meningitidis serogroup A disease Vaccine 22 2004 2171 2180
15. G. Norheim, E. Fritzsønn, P. Kristiansen, T. Tangen, D.A. Caugant, and E.A. Høiby Prevention of serogroup A, C, and W135 meningococcal disease in Africa with outer membrane vesicle vaccines M.A. Apicella H. Seifert Fourteenth International Pathogenic Neisseria Conference Milwaukee, Wisconsin, USA 2004 181
16. A. Antignac, M. Ducos-Galand, A. Guiyoule, R. Pires, J.M. Alonso, and M-K. Taha Neisseria meningitidis strains isolated from invasive infections in France (1999-2002): phenotypes and antibiotic susceptibility patterns Clin Infect Dis 37 2003 912 920
17. K. Cartwright, R. Morris, H. Rumke, A. Fox, R. Borrow, and N. Begg Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins Vaccine 17 1999 2612 2619
18. M. Pizza, V. Scarlato, V. Masignani, M.M. Giuliani, B. Arlicò, and M. Comanducci Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing Science 287 2000 1816 1820